Whetstone Capital Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-70,065
Closed -$4.7M 32
2024
Q3
$4.7M Buy
70,065
+59,093
+539% +$4.85M 2.26% 18
2024
Q2
$1.24M Buy
10,972
+46
+0.4% +$5.82K 0.58% 30
2024
Q1
$1.51M Buy
10,926
+5,251
+93% +$660K 0.66% 23
2023
Q4
$704K Buy
+5,675
New +$580K 0.35% 25

Other funds holding DXCM

Whetstone Capital Advisors's DXCM Position: Q4 2024 in Review

Whetstone Capital Advisors sold out of DexCom (DXCM) in Q4 2024, closing a stake of 70,065 shares — an estimated $4.7M sold.

Whetstone Capital Advisors first reported a position in DXCM in Q4 2023 and held it in 4 quarters. The position peaked at $4.7M in Q3 2024. 950 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

  • Whetstone Capital Advisors reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
  • Whetstone Capital Advisors sold 70,065 DexCom shares in Q4 2024, an estimated $4.7M.
  • Whetstone Capital Advisors first reported a position in DexCom in Q4 2023 and held it in 4 quarters.
  • Whetstone Capital Advisors's DexCom position peaked at $4.7M in Q3 2024.
  • 950 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Whetstone Capital Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.